FCF Grants Awarded to Johns Hopkins University
Total grants: 10
- A therapeutic cancer vaccine plus ipilimumab and nivolumab for fibrolamellar hepatocellular carcinoma (FLC) — Principal investigator(s): Mark Yarchoan, Marina Baretti — 2025
- Exploiting a Critical Vulnerability to Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC) — Principal investigator(s): Marina Baretti, Mark Yarchoan — 2023
- Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinoma — Principal investigator(s): Praveen Sethupathy, Mark Yarchoan, Paul G. Thomas — 2022
- Clinical trial protocol development — Principal investigator(s): Mark Yarchoan — 2022
- Development and validation of an orthotopic, syngeneic, mouse model for fibrolamellar hepatocellular carcinoma — Principal investigator(s): Mark Yarchoan — 2021
- A Pilot Study of a DNAJB1-PRKACA fusion kinase vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar carcinoma (FLC) — Principal investigator(s): Mark Yarchoan — 2019
- Investigating immune checkpoint biomarkers in tissue and peripheral blood of patients with fibrolamellar hepatocellular carcinoma — Principal investigator(s): Amy K. Kim — 2016
- Generation of T cells with specificity to FLC’s chimeric fusion — Principal investigator(s): Ephraim Fuchs — 2015
- Sequential related donor partial liver followed by bone marrow transplantation for treatment of extensive, liver-confined fibrolamellar hepatocellular carcinoma (FL-HCC) — Principal investigator(s): Ephraim Fuchs — 2014
- Blood markers for fibrolamellar — Principal investigator(s): Michael Torbenson — 2010
This list represents the complete set of Fibrolamellar Cancer Foundation grants awarded to Johns Hopkins University.